Risk of progression of Barrett's esophagus in patients with cirrhosis

被引:3
|
作者
Apfel, Tehilla [1 ]
Lopez, Rocio [1 ]
Sanaka, Madhusudhan R. [1 ]
Thota, Prashanthi N. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA
关键词
Liver cirrhosis; Barrett's esophagus; Dysplasia; Esophageal neoplasm; Progression; NONALCOHOLIC FATTY LIVER; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX; METABOLIC SYNDROME; ADENOCARCINOMA; VARICES; METAANALYSIS; ADIPOKINES; DISEASE;
D O I
10.3748/wjg.v23.i18.3287
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To study Barrett's esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1: 4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/ EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person-years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person-years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR = 7.9, 95% CI: 2.0-30.9, P = 0.003). CONCLUSION Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients.
引用
收藏
页码:3287 / 3294
页数:8
相关论文
共 50 条
  • [1] Risk of progression of Barrett's esophagus in patients with cirrhosis
    Tehilla Apfel
    Rocio Lopez
    Madhusudhan R Sanaka
    Prashanthi N Thota
    World Journal of Gastroenterology, 2017, (18) : 3287 - 3294
  • [2] Histological features indicate the risk of progression of patients with Barrett's esophagus
    Chen, Tiane
    Ly, Hong
    Stairs, Douglas B.
    Jackson, Christopher R.
    Chen, Guoli
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 266 : 155812
  • [3] Predictors of Progression in Barrett’s Esophagus
    Subhankar Chakraborty
    Prasad G. Iyer
    Current Treatment Options in Gastroenterology, 2019, 17 (1) : 18 - 31
  • [4] The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression
    Ramzan, Zeeshan
    Nassri, Ammar B.
    Huerta, Sergio
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (05) : 575 - 591
  • [5] Symptoms and Endoscopic Features at Barrett's Esophagus Diagnosis: Implications for Neoplastic Progression Risk
    Coleman, Helen G.
    Bhat, Shivaram K.
    Murray, Liam J.
    McManus, Damian T.
    O'Neill, Orla M.
    Gavin, Anna T.
    Johnston, Brian T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) : 527 - 534
  • [6] Management of cancer risk in Barrett's esophagus
    Tan, Alyisha
    Macrae, Finlay
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (10) : 1485 - 1492
  • [7] Clinical prediction model for tumor progression in Barrett's esophagus
    Holmberg, Dag
    Ness-Jensen, Eivind
    Mattsson, Fredrik
    Lagergren, Jesper
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2019, 33 (09): : 2901 - 2908
  • [8] Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance
    Gatenby, Piers
    Bhattacharjee, Santanu
    Wall, Christine
    Caygill, Christine
    Watson, Anthony
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (48) : 10592 - 10600
  • [9] Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women
    Allen, James E.
    Desai, Madhav
    Roumans, Carlijn A. M.
    Vennalaganti, Sreekar
    Vennalaganti, Prashanth
    Bansal, Ajay
    Falk, Gary
    Lieberman, David
    Sampliner, Richard
    Thota, Prashanthi
    Vargo, John
    Gupta, Neil
    Moawad, Fouad
    Bruno, Marco
    Kennedy, Kevin F.
    Gaddam, Srinivas
    Young, Patrick
    Mathur, Sharad
    Cash, Brooks
    Spaander, Manon
    Sharma, Prateek
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (04) : 321 - 326
  • [10] Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
    Nguyen, Dang M.
    El-Serag, Hashem B.
    Henderson, Louise
    Stein, Daniel
    Bhattacharyya, Achyut
    Sampliner, Richard E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (12) : 1299 - 1304